Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers27. February 2019|In Portfolio News|By eazee-designstudioImmatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers. IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced/ metastatic solid tumors. PrevNext
